---
title: "Tempus AI Launches Paige Predict to Advance Digital Pathology"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273237126.md"
datetime: "2026-01-21T13:30:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273237126.md)
  - [en](https://longbridge.com/en/news/273237126.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273237126.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273237126.md) | [繁體中文](https://longbridge.com/zh-HK/news/273237126.md)


# Tempus AI Launches Paige Predict to Advance Digital Pathology

Tempus AI Inc. has announced the launch of Paige Predict, a new suite of digital pathology applications designed to analyze H&E whole slide images and help inform testing decisions in cancer care. The AI-powered platform predicts the presence or absence of clinically relevant biomarkers from a single slide, aiding physicians even when tissue samples are limited. Built using Paige’s foundation model and a combined dataset from both Tempus and Paige, Paige Predict leverages data from over 200,000 patients and covers 123 biomarkers across 16 cancer types. This launch follows Tempus’s acquisition of Paige and represents an expansion of the company’s offerings in digital pathology and precision medicine. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121403553) on January 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares US Healthcare Providers ETF (IHF.US)](https://longbridge.com/en/quote/IHF.US.md)
- [Tempus AI, Inc. (TEM.US)](https://longbridge.com/en/quote/TEM.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares Genomics Immnlgy & Hlthcr ETF (IDNA.US)](https://longbridge.com/en/quote/IDNA.US.md)
- [Tradr 2X Long TEM Daily ETF (TEMT.US)](https://longbridge.com/en/quote/TEMT.US.md)

## Related News & Research

- [Tempus AI stock near 1-year low: Cathie Wood’s ARK buys more while offloading Nvidia, Meta, other tech plays](https://longbridge.com/en/news/280727846.md)
- [Tempus AI Insider Sold Shares Worth $7,711,150, According to a Recent SEC Filing](https://longbridge.com/en/news/280974954.md)
- [Tempus AI (TEM) Valuation Check After Daiichi Sankyo Oncology Collaboration Announcement](https://longbridge.com/en/news/281281204.md)
- [BUZZ-Tempus AI rises after study shows AI-driven alerts improve heart valve treatment](https://longbridge.com/en/news/281390073.md)
- [Allworth Financial LP Reduces Holdings in Biodesix, Inc. $BDSX](https://longbridge.com/en/news/281318320.md)